Prevalence of Metallo Beta-Lactamase in Clinical Isolates of Non-Fermenters in A Tertiary Care Hospital
Prevalence of Metallo Beta-Lactamase in Clinical Isolates of Non-Fermenters in A Tertiary Care Hospital
DOI:
https://doi.org/10.70284/njirm.v8i2.1225Keywords:
Carbapenem resistance, MBL, Non-FermentersAbstract
Background & objectives: Metallo-beta-lactamase (MBL) producing Pseudomonas Spp. and Acinetobacter spp. have become a growing therapeutic concern worldwide. Therefore, an attempt has been made in this study to identify metallo beta-lactamases in carbapenem resistant isolates of non-fermenters. Methods: During July-September 2016, out of total 4869 clinical isolates, non-fermenters were 1353. All the non-fermenters were subjected to antibiotic susceptibility testing by Kirby-Bauer disc diffusion test as per the Clinical and Laboratory Standards Institute (CLSI) guidelines. Selection criteria for MBL detection among these isolates was resistance to imipenem. Imipenem resistant isolates were tested for the detection of MBL production by Imipenem-EDTA combined disc method, double-disc synergy test and minimum inhibitory concentration (MIC) of imipenem was determined by E-strip. Enhancement of inhibition zone around imipenem discs impregnated with EDTA as compared to those without EDTA confirmed MBL production. Results: Out of 1353 non-fermenter isolates from various clinical specimens, 920(68%) were Pseudomonas spp. and 433(32%) were Acinetobacter spp. They were identified by using standard microbiological techniques. Out of 920 Pseudomonas spp., Imipenem resistance was found in 208(22.61%) isolates. MBL detection test was performed on these 208 isolates & 120 (13.04%) were MBL positive. Out of 433 Acinetobacter spp., Imipenem resistance was found in 172 (39.72%) isolates. MBL detection test was performed on these 172 isolates & 133(30.71%) were MBL positive. Interpretation & conclusion: MBL-mediated imipenem resistance in Pseudomonas spp. and Acinetobacter spp. is a cause for concern in the therapy of patients. Therefore, a strict antibiotic policy should be followed to prevent further spread of MBLs. Therapeutic options for such isolates are Colistin and Polymyxin B for Pseudomonas spp. and Colistin, Polymyxin B and Tigecycline for Acinetobacter spp. [Rathod R NJIRM 2017; 8(2):149-152]
References
2. Hakima Kabbaj, Myriam Seffar, Bouchra Belefquih, Dalal Akka, Najat Handor, Morad Amor, Ahmed Essaid Alaoui. Prevalence of Metallo-β-Lactamases Producing Acinetobacter baumani in a Moroccan Hospital. ISRN Infectious Diseases Volume 2013 (2013), Article ID 154921, 3 pages.
3. Ghadage Dnyaneshwari P, Muley Vrishali A, Bhore Arvind V. Metallo-Beta Lactamase Producing Clinical Isolates of Pseudomonas aeruginosa from Intensive Care Unit Patients of a Tertiary Care Hospital. NJLM/2014/8943:2009
4. Pooja Singla, Rama Sikka, Antariksh Deep and Uma Chaudhary. Phenotypic Detection and Prevalence of Metallo beta-Lactamases (Mbls) In Carbapenem Resistant Isolates of Acinetobacter Species at A Tertiary Care Hospital in North India. Int. J. Pharm. Med. & Bio. Sc. 2013.
5. M.J.C. Noyal, G.A. Menezes, B.N. Harish, S. Sujatha & S.C. Parija. Simple screening tests for detection
of carbapenemases in clinical isolates of nonfermentive Gram-negative bacteria. Indian J Med Res 129, June 2009, pp 707-712
6. Amarjeet Kaur, Veenu Gupta, and Deepinder Chhina. Prevalence of metallo- β-lactamase-producing (MBL) Acinetobacter species in a tertiary care hospital. Iran J Microbial. 2014 Feb; 6(1): 22–25.
7. Varsha Gupta, Nidhi Singla, Jagdish Chander. Use of two double disc synergy tests to detect metallo beta lactamases in non-fermenters. Indian J Med Res 128, November 2008, pp 671-672
8. Johnson AP1, Woodford N. Global spread of antibiotic resistance: the example of New Delhi metallo-β-lactamase (NDM)-mediated carbapenem resistance. J Med Microbiol. 2013 Apr;62(Pt 4):499-513. doi: 10.1099/jmm.0.052555-0. Epub 2013 Jan 17.
